Correlation Between Crispr Therapeutics and Pacific Biosciences

Can any of the company-specific risk be diversified away by investing in both Crispr Therapeutics and Pacific Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Crispr Therapeutics and Pacific Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Crispr Therapeutics AG and Pacific Biosciences of, you can compare the effects of market volatilities on Crispr Therapeutics and Pacific Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Crispr Therapeutics with a short position of Pacific Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Crispr Therapeutics and Pacific Biosciences.

Diversification Opportunities for Crispr Therapeutics and Pacific Biosciences

0.66

Correlation Coefficient

Crispr Therapeutics  Pacific Biosciences

Poor diversification

The 3 months correlation between Crispr and Pacific is 0.66. Overlapping area represents the amount of risk that can be diversified away by holding Crispr Therapeutics AG and Pacific Biosciences of in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Pacific Biosciences and Crispr Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Crispr Therapeutics AG are associated (or correlated) with Pacific Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Pacific Biosciences has no effect on the direction of Crispr Therapeutics i.e., Crispr Therapeutics and Pacific Biosciences go up and down completely randomly.

Pair Corralation between Crispr Therapeutics and Pacific Biosciences

Given the investment horizon of 90 days Crispr Therapeutics AG is expected to under-perform the Pacific Biosciences. But the stock apears to be less risky and, when comparing its historical volatility, Crispr Therapeutics AG is 1.74 times less risky than Pacific Biosciences. The stock trades about -0.12 of its potential returns per unit of risk. The Pacific Biosciences of is currently generating about 0.0 of returns per unit of risk over similar time horizon. If you would invest  246.00  in Pacific Biosciences of on September 12, 2024 and sell it today you would lose (12.00) from holding Pacific Biosciences of or give up 4.88% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Crispr Therapeutics AG  vs.  Pacific Biosciences of

Crispr Therapeutics

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Crispr Therapeutics AG are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating basic indicators, Crispr Therapeutics may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pacific Biosciences

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Pacific Biosciences of are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak fundamental indicators, Pacific Biosciences sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Crispr Therapeutics and Pacific Biosciences

The main advantage of trading using opposite Crispr Therapeutics and Pacific Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Crispr Therapeutics position performs unexpectedly, Pacific Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pacific Biosciences will offset losses from the drop in Pacific Biosciences' long position.

The idea behind Crispr Therapeutics AG and Pacific Biosciences of pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.